Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Flosequinan
Introduction
Overview
Overview
Flosequinan is a quinolone vasodilator. It has direct relaxing effects on peripheral arteries and veins. It is administered orally in cases of congestive heart failure in patients who are not responsive to digitalis or ACE inhibitors. It was sold under the trade name Manoplax.
It was withdrawn from the US market in October 1993 due to an increased risk of hospitalization or death.[1]
Synthesis
Synthesis
Both methods for forming the heterocyclic ring in quinolones involved cyclization into the carbocyclic ring. A closely related quinolone that displays cardiovascular rather than antibiotic activity is constructed by a condensation that closes the bond at the 2,3 position in the heterocyclic ring.
![700px U.S. Patent 5,079,264 N.B.[2]](https://www.wikidoc.org/index.php/File%3AFlosequinan_Syn.png)
The starting material (2) is obtained by reaction of the aminoacetophenone derivative (1) with ethyl formate. Heating the product in ethylene glycol methyl ether leads to an aldol-like cyclization and the formation of a quinolone ring. The product, flosequinan (3), displays vasodilator and cardiotonic activities.
References
References
- ↑ “Heart drug withdrawn – Boots Pharmaceuticals’ Manoplax”. FDA Consumer. 1993. Retrieved 2008-12-01.
- ↑ http://www.druglead.com/cds/flosequinan.html
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]